Dr. Jonathan Wade Bress, MD

Dr. Bress practices at Rochester General Hospital in Rochester, New York, part of Rochester Regional Health.

Dr. Bress' NPI, 1326101007, was assigned on December 18, 2006. Dr. Bress graduated from Weill Cornell Medicine in 2002. Dr. Bress' New York license number on file is 230995.

Dr. Bress' primary practice is Rochester General Hospital, at 1425 Portland Avenue, Rochester, NY 14621 in Monroe County. The practice phone is (585) 922-4000.

Dr. Bress' primary practice is Rochester General Hospital in Rochester, New York, part of Rochester Regional Health. Dr. Bress is also affiliated with Unity Hospital. The medical group on file is Rochester General Hospital. Dmand AI also links Dr. Bress to 1 more hospital, 2 dialysis centers and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bress practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Bress' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Bress is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bress' licenses on file in 2 states: New York and Pennsylvania.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia, kidney cysts and kidney disease among the conditions Dr. Bress treats.

CMS data shows 737 Medicare services from Dr. Bress across 8 procedure codes in 2024, for 231 Medicare patients. Medicare paid $86,525 for them.

CMS counts 231 Medicare patients who saw Dr. Bress in 2024. The largest group is 75 to 84, with 72 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 48% are also on Medicaid. Their average risk score is 5.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bress' median patient age at 74, with 47% women.

In 2024, Dr. Bress wrote 1,558 Medicare Part D claims for 335 patients. 78% of them were for generic drugs. CMS names the drug for 1,373 of them, across 24 drugs with 11 or more claims each, at $197,910 in total drug cost. In 2023, CMS named 1,051 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Bress for performance year 2024, reported through an alternative payment model (APM). Dr. Bress accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bress as offering telehealth.

Dmand AI links 17 papers to Dr. Bress, published from 2018 to 2025. 2018 was the busiest year, with 4. The most frequent topics are COVID-19, SARS-CoV-2 and Epinephrine. Dr. Bress has published most often in Am J Kidney Dis. Dr. Bress' most frequent co-authors are Saad Jamshed, MD, John Hanna, MD and Richard H. Sterns, MD.

Dmand AI links Dr. Bress to 1 clinical trial. Conditions studied include Clostridium Infections and Gram-Positive Bacterial Infections.

CMS Open Payments shows 19 general payments to Dr. Bress from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 97% of the total. Sanofi and Genzyme US Companies paid the most, $134.

Dr. Bress graduated from Weill Cornell Medicine in 2002.

Dr. Bress is in network with 17 carriers, including Aetna, Elevance and MVP Health Care. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.